JP7141408B2 - 前立腺癌の併用療法 - Google Patents
前立腺癌の併用療法 Download PDFInfo
- Publication number
- JP7141408B2 JP7141408B2 JP2019555852A JP2019555852A JP7141408B2 JP 7141408 B2 JP7141408 B2 JP 7141408B2 JP 2019555852 A JP2019555852 A JP 2019555852A JP 2019555852 A JP2019555852 A JP 2019555852A JP 7141408 B2 JP7141408 B2 JP 7141408B2
- Authority
- JP
- Japan
- Prior art keywords
- niraparib
- patient
- pharmaceutical composition
- prednisone
- abiraterone acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022117192A JP7407880B2 (ja) | 2017-04-13 | 2022-07-22 | 前立腺癌の併用療法 |
| JP2023196574A JP2024023344A (ja) | 2017-04-13 | 2023-11-20 | 前立腺癌の併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485164P | 2017-04-13 | 2017-04-13 | |
| US62/485,164 | 2017-04-13 | ||
| PCT/US2018/026661 WO2018191141A1 (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022117192A Division JP7407880B2 (ja) | 2017-04-13 | 2022-07-22 | 前立腺癌の併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516646A JP2020516646A (ja) | 2020-06-11 |
| JP2020516646A5 JP2020516646A5 (enExample) | 2021-07-26 |
| JP7141408B2 true JP7141408B2 (ja) | 2022-09-22 |
Family
ID=62067858
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555852A Active JP7141408B2 (ja) | 2017-04-13 | 2018-04-09 | 前立腺癌の併用療法 |
| JP2022117192A Active JP7407880B2 (ja) | 2017-04-13 | 2022-07-22 | 前立腺癌の併用療法 |
| JP2023196574A Pending JP2024023344A (ja) | 2017-04-13 | 2023-11-20 | 前立腺癌の併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022117192A Active JP7407880B2 (ja) | 2017-04-13 | 2022-07-22 | 前立腺癌の併用療法 |
| JP2023196574A Pending JP2024023344A (ja) | 2017-04-13 | 2023-11-20 | 前立腺癌の併用療法 |
Country Status (33)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322013A (en) | 2016-07-29 | 2025-09-01 | Janssen Pharmaceutica Nv | Niraparib or its salts for use in the treatment of prostate cancer |
| WO2020139339A1 (en) * | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer |
| JP7442328B2 (ja) * | 2020-02-03 | 2024-03-04 | 株式会社三共 | 遊技機 |
| CN113546037B (zh) * | 2020-04-20 | 2024-12-27 | 鲁南制药集团股份有限公司 | 一种醋酸阿比特龙栓剂及其制备方法 |
| UA130040C2 (uk) * | 2020-05-08 | 2025-10-22 | Янссен Фармацевтика Нв | Види лікування раку передміхурової залози за допомогою комбінацій абіратерону ацетату та нірапарибу |
| CN114306236B (zh) * | 2021-12-15 | 2022-10-21 | 湖南慧泽生物医药科技有限公司 | 用于负载醋酸阿比特龙的自微乳体系及组合物和应用 |
| TWI828471B (zh) | 2021-12-15 | 2024-01-01 | 大陸商湖南慧澤生物醫藥科技有限公司 | 醋酸阿比特龍的自微乳組合物和應用 |
| CA3254950A1 (en) * | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Polytherapy for the treatment of cancer |
| WO2024203348A1 (ja) * | 2023-03-31 | 2024-10-03 | ソニーグループ株式会社 | 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法 |
| WO2025027138A1 (en) * | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501575A (ja) | 2006-08-25 | 2010-01-21 | クオウガル バイオテクノロジー，インコーポレイテッド | 癌を治療するための方法及び組成物 |
| JP2010515715A (ja) | 2007-01-10 | 2010-05-13 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| JP5989965B2 (ja) | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| US9314473B2 (en) * | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| WO2014089324A1 (en) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
-
2017
- 2017-06-16 JO JOP/2019/0244A patent/JOP20190244A1/ar unknown
-
2018
- 2018-04-09 EP EP22200801.3A patent/EP4176878A1/en active Pending
- 2018-04-09 MY MYPI2023006196A patent/MY209010A/en unknown
- 2018-04-09 PL PL18720895.4T patent/PL3609497T3/pl unknown
- 2018-04-09 PE PE2019002030A patent/PE20200444A1/es unknown
- 2018-04-09 RS RS20221127A patent/RS63832B1/sr unknown
- 2018-04-09 EA EA201992430A patent/EA201992430A1/ru unknown
- 2018-04-09 EP EP18720895.4A patent/EP3609497B1/en active Active
- 2018-04-09 LT LTEPPCT/US2018/026661T patent/LT3609497T/lt unknown
- 2018-04-09 MD MDE20200190T patent/MD3609497T2/ro not_active IP Right Cessation
- 2018-04-09 JP JP2019555852A patent/JP7141408B2/ja active Active
- 2018-04-09 EP EP22200882.3A patent/EP4176879A1/en not_active Withdrawn
- 2018-04-09 MX MX2019012296A patent/MX2019012296A/es unknown
- 2018-04-09 WO PCT/US2018/026661 patent/WO2018191141A1/en not_active Ceased
- 2018-04-09 UA UAA201911057A patent/UA129514C2/uk unknown
- 2018-04-09 HR HRP20221327TT patent/HRP20221327T1/hr unknown
- 2018-04-09 CA CA3059562A patent/CA3059562A1/en active Pending
- 2018-04-09 KR KR1020197032257A patent/KR20190134718A/ko not_active Ceased
- 2018-04-09 CN CN202411589875.XA patent/CN119235874A/zh active Pending
- 2018-04-09 CN CN201880039365.1A patent/CN110753545A/zh active Pending
- 2018-04-09 AU AU2018251594A patent/AU2018251594A1/en not_active Abandoned
- 2018-04-09 ES ES18720895T patent/ES2931052T3/es active Active
- 2018-04-09 SG SG11201909552V patent/SG11201909552VA/en unknown
- 2018-04-09 PT PT187208954T patent/PT3609497T/pt unknown
- 2018-04-09 HU HUE18720895A patent/HUE060460T2/hu unknown
- 2018-04-09 SM SM20220467T patent/SMT202200467T1/it unknown
- 2018-04-09 MA MA48728A patent/MA48728B1/fr unknown
- 2018-04-09 CR CR20190467A patent/CR20190467A/es unknown
- 2018-04-09 IL IL320452A patent/IL320452A/en unknown
- 2018-04-09 DK DK18720895.4T patent/DK3609497T3/da active
- 2018-04-09 IL IL269879A patent/IL269879B2/en unknown
- 2018-04-11 US US15/950,707 patent/US20180296574A1/en active Pending
-
2019
- 2019-10-08 CL CL2019002871A patent/CL2019002871A1/es unknown
- 2019-10-09 NI NI201900105A patent/NI201900105A/es unknown
- 2019-10-10 PH PH12019502317A patent/PH12019502317A1/en unknown
- 2019-10-14 MX MX2023009569A patent/MX2023009569A/es unknown
- 2019-10-14 DO DO2019000264A patent/DOP2019000264A/es unknown
- 2019-10-18 CO CONC2019/0011591A patent/CO2019011591A2/es unknown
-
2022
- 2022-02-25 US US17/680,553 patent/US20220175801A1/en not_active Abandoned
- 2022-07-22 JP JP2022117192A patent/JP7407880B2/ja active Active
-
2023
- 2023-11-20 JP JP2023196574A patent/JP2024023344A/ja active Pending
-
2024
- 2024-02-01 US US18/429,778 patent/US20240245710A1/en active Pending
- 2024-04-11 AU AU2024202346A patent/AU2024202346A1/en active Pending
- 2024-08-09 US US18/799,339 patent/US20240398837A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501575A (ja) | 2006-08-25 | 2010-01-21 | クオウガル バイオテクノロジー，インコーポレイテッド | 癌を治療するための方法及び組成物 |
| JP2010515715A (ja) | 2007-01-10 | 2010-05-13 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
Non-Patent Citations (9)
| Title |
|---|
| Asian Journal of Andrology，2014年，16，pp.401-406 |
| Asia-Pac J Clinn Oncol，2012年，8(Suppl.1)，p.33(112) |
| ClinicalTrials.gov, NCT01576172，2012年04月12日 |
| ClinicalTrials.gov, NCT02924766，2016年10月05日 |
| Drugs of the Future，2013年，38(10)，pp.679-685 |
| Journal of Clinical Oncology，2016年，34(15 suppl.) Abstract 5010 |
| Lancet Oncol，2012年，13，pp.1210-1217 |
| Lancet Oncol，2015年，16，pp.152-160 |
| The Oncologist，2014年，19，pp.1231-1240 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7141408B2 (ja) | 前立腺癌の併用療法 | |
| Hoy | Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer | |
| JP2016515586A (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| JP2024510612A (ja) | ソトラシブ投与レジメン | |
| JP2022518235A (ja) | 進行期固形腫瘍がんの治療用ｒｎａ | |
| US20250235451A1 (en) | Methods of Delaying Pain Progression And Treating Prostate Cancer | |
| HK40092155A (en) | Combination therapy for prostate cancer | |
| Lu et al. | Efficacy and safety of anti–programmed death-ligand 1 monoclonal antibody socazolimab with carboplatin and Etoposide for extensive-stage SCLC: results from the phase 1b clinical trial | |
| EA044835B1 (ru) | Комбинированная терапия рака предстательной железы | |
| BR112019021466B1 (pt) | Composição compreendendo niraparibe, acetato de abiraterona, e prednisona, bem como uso dos referidos compostos | |
| Rove et al. | A renaissance in the medical treatment of advanced prostate cancer | |
| US20230241063A1 (en) | Methods of treating prostate cancer | |
| CN116981462A (zh) | 索托拉西布给药方案 | |
| JP2024534456A (ja) | 卵巣がん及び他のがんの治療のためのグルココルチコイド受容体モジュレーターの間欠投与 | |
| WO2024173931A2 (en) | Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations | |
| CN118076355A (zh) | 用于治疗前列腺癌的cyp11a1抑制剂 | |
| Attard et al. | Improving the Outcome of Patients with Castration-resistant Prostate Cancer Through Rational Targeting of the Androgen Receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210408 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210512 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220425 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220627 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220809 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220908 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220909 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7141408 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |